和鉑醫藥(02142.HK)新型藥物完成II期試驗治療甲狀腺眼病首次給藥
和鉑醫藥(02142.HK)公佈,巴託利單抗(HBM9161,一款由公司開發用於自身免疫性疾病療法的新型藥物)用於治療甲狀腺眼病的臨牀II期試驗中,完成了首名患者的首次給藥。
該臨牀試驗旨在評估巴託利單抗(HBM9161)在治療中國甲狀腺眼病患者時的療效及安全性。
作爲產品管線的一部分,公司正在開發巴託利單抗(HBM9161),用於治療多種有大量未獲滿足醫療需求的且由致病性IgG介導的自身免疫性疾病。正於中國針對適應症開發候選藥物,而甲狀腺眼病爲當中首批展開研究的適應症之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.